Skip to content
CancerIndex

Publication

Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.

Authors not recorded

Clin Cancer Res2007PMID 17202311stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (3)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 3

Curated evidence

Evidence citing this paper (1)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
17202311
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
PIK3CA H1047R1
(prognostic)Malignant Breast NeoplasmPrognosticBSupports Better Outcome2accepted
EID2100

In Japanese invasive breast cancer patients, PIK3CA mutation was associated with improved relapse-free survival (p < .05).

PMID 17202311 · Maruyama et al., 2007 · Open in CIViC

civic